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ear Sir,
The article published in Reproductive Toxicology entitled, In
itro and in vivo reproduction toxicology of 12 monoaminergic reup-
ake inhibitors: Possible mechanisms of infrequent cardiovascular
nomalies by Sloot et al. [1], presents the authors’ views in deter-
ining the teratogenicity of a group of drugs utilizing whole
mbryo culture (WEC). The authors used a well-described pro-
ocol for WEC utilizing ﬁve exposures ranging from 0–9g/mL
o 0–100g/mL. For example, the ﬁve exposures for ﬂuoxe-
ine and paroxetine were 0g/mL, 0.3g/mL, 1g/mL, 3g/mL
nd 9g/mL and for mazindol and venlafaxine were 0g/mL,
0g/mL, 30g/mL, 60g/mL, and 100g/mL. The rat embryos
ere harvested at 9.5 days and grown for 48h at which time
hey were evaluated. The effects of the drugs were labeled as
mbryotoxic, potentially teratogenic or teratogenic. It is appropri-
te to label pathologic ﬁndings at 48h as an embryotoxic effect.
owever you cannot label WEC pathologic ﬁndings as poten-
ially teratogenic unless you have data indicating that the embryo
ill survive to a viable stage. Even more important you cannot
abel a chemical or drug as a teratogen unless you have evidence
hat the embryo will survive the exposure during organogen-
sis as a malformed fetus. Of course, some embryotoxins can
ause the embryo to die with malformations before viability is
eached.
Sloot et al. all believe that they can demonstrate a terato-
enic effect using WEC since the authors labeled toxicological
ndings in the cultured embryos as evidence of a teratogenic
ffect. While it is true that the authors of this paper used the
erm embryotoxicity and potential teratogenicity in many places
n the paper, they also describe paroxetine as a teratogen. Let
e quote from the paper the following two sentences. “In vitro,
aroxetine and the positive control retinol were the only com-
ounds identiﬁed as a clear teratogen” (Abstract). In paragraph
.1.2 under the Results section the following statement is also
epeated, “Retinol and paroxetine were the only two compounds
dentiﬁed as clear teratogens.” This conclusion is inappropriate
ecause the whole-animal teratology studies cited by authors did
ot result in teratogenesis [2,3] and the exposures of paroxe-
ine and ﬂuoxetine in the WEC were greater than the exposures
hat occur in the human with these drugs. Furthermore, these
uthorswere unable to determinewhether the embryotoxic effects
bserved in WEC would result in lethality in vivo at these expo-
ures. You cannot utilize only the results of WEC to determine
uman teratogenic risks, unless the investigator is certain that the
xposure used in the WEC will not be lethal to the embryo in
ivo.
The use of WEC can have the following positive goals or pur-
oses.
890-6238/$ – see front matter © 2009 Elsevier Inc. All rights reserved.
oi:10.1016/j.reprotox.2009.11.010(1) Investigators who have produced congenital malformation in
pregnant animals such as the rat after administering a drug or
chemical can utilize whole embryo culture to determine the
mechanism of action of the teratogenic effect. The ﬁrst pub-
lication using the roller tube WEC technique was published
in 1972 using teratogenic kidney antibodies that were potent
teratogens when injected into pregnant rats early in gestation
[4–9]. The article describing these experiments was published
by New and Brent and demonstrated that the mechanism of
embryotoxicity was interference with the yolk sac function
and not a direct effect on the embryo. Once teratogenicity
was demonstrated in a whole-animal model, exposures of yolk
sac antibodies in WEC at the levels that occur in the circula-
tion of the whole-animal model permitted the investigators to
determine the mechanism of action (MOA). If WEC had been
performed ﬁrst, before there was evidence that teratogenic
antibody had an effect in a whole-animal study, the results
would only indicate that the antiserum was embryotoxic. We
could not determine that it was teratogenic, because wewould
not know the level of teratogenic antibody that occurs in the
whole animal in order to select the proper exposure in the
embryo culture – andwewouldnot knowwhether the embryos
would survive to term at these exposures.
(2) The second purpose of embryo culture is for screening. When a
pharmaceutical companyprepares anewdrug, there frequently
are not large quantities of the drug available and, therefore, the
investigators cannot afford to utilize their restricted supply for
whole-animal teratology studies. Utilizing WEC to screen for
the embryotoxicity of the compound is perfectly appropriate;
because it gives the investigators an idea at what serum levels
they can observe or not observe embryotoxic effects.
(3) WEC can be used to study many aspects of pharmacoki-
netics and determining the putative teratogen. For example,
cyclophosphamide has been demonstrated to be teratogenic
in humans and rodents. However, the putative teratogen of
cyclophosphamide is its metabolic product phosphoramide
mustard, which is teratogenic in vivo and in WEC while
cyclophosphoramide is teratogenic in vivo but not in embryo
culture [10,11].
(4) WEC can be used to study many aspects of normal embry-
onic development. You cannotuse embryo culture todetermine
whether an agent is going to be teratogenic in a whole-animal
teratology study or in the human when you have no exposure
data available in either the human or the animal model at the
time that you initiate the WEC. The reason why utilizing WEC
as the ﬁrst project for determining teratogenicity and label-
ing an agent as a teratogen is inappropriate (when you do not
know whether it is teratogenic in a whole-animal model) is
because you have no idea whether the levels that produce an
embryotoxic effect in the WEC would be lethal to the embryo
in the whole-animal model. That is why the positive results
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of WEC results are described as an embryotoxic effect. Terato-
genicity infers that the abnormalities will be present at term in
the liveborn fetus or as a dead fetus later in pregnancy.
5) WEC can be used to describe the actual developmental changes
in the embryo that occur during organogenesis when exposed
to an embryotoxic agent.
If the authors had examined the package insert or the informa-
ion available in the Physician’s Desk Reference [12] they would
ave found the following information under the section of Phar-
acokinetics. When a human being is administered 30mg of
aroxetine that reaches the steady state, the Cmax level for paroxe-
ine is61.7ng/mL. Followingasingledoseofﬂuoxetineof40mg, the
eak plasma concentration ranges between 15 and 55ng/mL. In the
EC experimentswith paroxetine and ﬂuoxetine the investigators
sed the following concentrations: for paroxetine and ﬂuoxetine;
g/mL, 0.3g/mL, 1g/mL, 3g/mL and 9g/mL (Table 1 in
he Sloot paper). The results of these embryo culture experiments
ith paroxetine and ﬂuoxetine are stated as follows. “Paroxe-
ine at 3g/mL induced speciﬁc malformations (fused brachial
ar, swollen posterior neuropore) without signs of embryotoxic-
ty, demonstrating a teratogenic potential. At higher concentration
f 9g/mL, speciﬁc malformations such as displaced/additional
tic system and again brachial bar defects (fused or swollen) were
pparent. In the case of ﬂuoxetine, one embryo showed irregular
ormedbranchial bars at 1g/mLwithout signs of embryotoxicity.”
In the embryo culture experiments using paroxetine the inves-
igators had concentrations of paroxetine of 0.3g/mL, 1g/mL,
g/mL and 9g/mL. This is respectively 5 times, 16 times, 48
imes and 145 times the concentration that would be present in
he human. Similarly for ﬂuoxetine, if the same concentrations in
he embryo culture of 0.3g/mL, 1g/mL, 3g/mL and 9g/mL
ere used these concentrations are equal to 6 times, 20 times, 60
imes and 160 times the clinical serum levels of ﬂuoxetine.
It is interesting that the authors did not use the WEC that con-
ained serum concentrations that occur in humanswho are treated
ith these medications. Furthermore, they demonstrated quite
learly that they had to have very high levels of paroxetine and
uoxetine to produce any effects in embryo culture. There is no
rug or chemical that would not produce an embryotoxic effect if
he concentration were raised to very high levels. But teratogens
ave threshold exposures below, which no deleterious effects are
roduced [13] and the authors demonstrated that the NOAEL (no
dverse effect level) for embryotoxicity was far above the usual
uman exposures.
The most that we can conclude from WEC experiments if we
ave no evidence of teratogenicity from animal studies [2,3] or
nconsistent evidence from human epidemiology studies is to indi-
ate that a particular concentration of a drug or chemical is or is
ot embryotoxic, since we do not know if the embryo will survive
14,15]. The most important aspect of WEC is to utilize a serum
oncentration in the WEC that is similar to the serum level in the
xposed human or exposed animal model that has demonstrated
eratogenesis.
Although the animal teratology studies utilizing paroxetine and
uoxetine were negative [2,3], the authors still attempted to pro-
uce a “teratogenic effect” in a WEC model.
Could the authors explain how a drug can be teratogenic inWEC
ut not in vivo in an animalmodel?One of the reviewers of this Let-
er commented on Sloot et al.’s deﬁnition of teratogenicity. “A basic
rinciple of toxicological hazard identiﬁcation is to identify lesions
n tissues following high doses of xenobiotic. A no adverse effect
evel is then deﬁned in the species concerned. Regulatory in vivo
evelopmental toxicity studies are expected to show a degree of
oxicity at the highest dose levels [5]. Sloot et al. were justiﬁed in
aking a similar approach in their in vitro experiments. The restric-oxicology 29 (2010) 251–253
tive deﬁnition of teratogenicity used in this paper,” i.e. “A speciﬁc
malformation in the absence of effects on growth or development”
is valid within the context of the stated objectives of the experi-
ment.” Theproblemwith this restrictivedeﬁnitionof teratogenicity
is that it is not a scientiﬁcally valid deﬁnition and does not apply to
all teratogens.
You can have malformations caused by environmental agents
that are not associated with growth retardation and there may
not even be an increase in fetal loss during development. You can
have exposures that produce growth retardation and death but do
not result in live fetuses with congenital malformations. Why did
these investigators not expose the WEC to levels that occur in the
human when being treated with antidepressants. It is obvious that
if Sloot et al. would have found no effect at those levels the topic of
teratogenic potential and teratogenicity would not be relevant.
Another area of concern is the fact that the authors have
describedmalformations of the branchial arches as indications that
paroxetine can produce congenital heart disease. They provide no
data to support this concept. While neural crest migration prob-
lems and other hypothetical causes of congenital heart disease are
plausible mechanisms, they provide no evidence to support their
hypothesis. Furthermore, theydidnotobserveabnormalities of car-
diac development in the WEC, even with very high concentrations
of paroxetine.
The ﬁnal paragraph in the author’s abstract states the following:
“It is suggested that observed speciﬁc malformations in vitro (e.g.
branchial bars deformed, displaced or additional otic system), not
noted in any (historical) controls, may be early ontogenetic indica-
tors for infrequent CV-anomalies observed in vivo. Despite the low
incidence of anomalies in vitro or in vivo, theymay yet be clinically
relevant as in the case of paroxetine.”
Scientists should not draw conclusions from hypotheses. They
must have objective evidence in order to support their conclusions.
These authors have no evidence that in their WEC model that the
cardiovascular malformations were produced at even highly toxic
exposures. Furthermore, they have no evidence that at lower expo-
sures that are still much higher than would be experienced by
humans, that cardiovascular abnormalities or any malformations
would be observed in viable fetuses in later stage pregnancies.
1. Summary
1. WEC has many useful scientiﬁc purposes.
2. You cannot utilizeWEC to label a drug or chemical as a teratogen
if the exposures utilized will result in embryonic or fetal death
in vivo.
3. WEC can indicate that a drug or chemical is embryotoxic.
4. If the exposure level for clinical use of a drug or environmen-
tal exposure of a chemical is known, it should be used in WEC
studies along with higher exposures as well.
5. You cannot predict that a drug is a cardiac teratogen from
WEC when no cardiac malformations are observed, as in this
study. You can generate many hypotheses, but unfortunately
the hypotheses generated by Sloot et al. will not make cardiac
malformations appear in their WEC experiments.
6. If whole-animal teratology studies are negative with clinically
appropriate exposures, WEC cannot provide information that
will label the drug as a teratogen.
Conﬂict of interest statementI was contacted by Lilly Pharmaceuticals 5 years ago to com-
ment on the results of an ATSDR (Agency for Toxic Substance and
DiseaseRegistry) committee report that reviewed thedevelopmen-
tal effects of ﬂuoxetine. The committee was convened by ATSDR
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o examine whether the water supply content of ﬂuoxetine rep-
esented a reproductive risk. I was paid a consultation fee for my
eview.
I was contacted by Glaxo-Smith Kline 2 years ago to review the
iterature dealing with the developmental effects of paroxetine. I
ave not received any payment for services for this consultation
xcept for travel expenses to one meeting.
Sincerely,
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